Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background: Type 2 diabetes is associated with an increased risk for Alzheimer’s disease (AD). Regulation of normal insulin function may be important in reducing the prevalence of dementia due to AD, particularly in individuals who harbor genetic risk for or have a parental family history of AD. The relationship between insulin resistance (IR) and AD pathology remains poorly understood, particularly in midlife prior to the onset of clinical metabolic disease or cognitive decline. Objective: We examined associations between IR as indexed by HOMA-IR, cerebrospinal fluid (CSF) biomarkers of AD pathology, and memory in middle-aged adults enriched for AD. We postulated that higher HOMA-IR and APOE ɛ 4 carriage would be associated with greater CSF AD pathology and poor memory performance. Methods: Cognitively asymptomatic middle-aged adults ( N = 70, mean age = 57.7 years) from the Wisconsin Alzheimer’s Disease Research Center with a parental family history of dementia due to AD underwent lumbar puncture, blood draw, and neuropsychological testing. CSF AD biomarkers including soluble amyloid-β protein precursor β (sAβPPβ), amyloid-β 42 (Aβ 42 ), and phosphorylated tau (P-tau 181 ) were examined with respect to HOMA-IR and APOE ɛ 4 status. Delayed memory performance was examined with respect to HOMA-IR, CSF AD biomarkers, and APOE ɛ 4 status. Results: Higher HOMA-IR was associated with higher sAβPPβ and Aβ 42 . APOE ɛ 4 carriers had significantly higher levels of sAβPP α , sAβPPβ, and P-tau 181 /Aβ 42 compared to noncarriers. The concurrent presence of higher HOMA-IR and CSF AD pathology predicted worse delayed memory performance. Conclusion: Overall, the findings suggest that IR and APOE ɛ 4 are contributing factors to the development of AD pathology in midlife, and provide support for targeting insulin function as a potentially modifiable risk factor for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Such studies are needed, given that IR may induce neurodegeneration prior to the onset of marked cognitive or behavioral impairment, and that the window for effectively modifying IR precedes the clinical diagnosis of type 2 diabetes [9].”
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 3×
“Diabetes and related conditions such as IR are associated with an increased relative risk for develop-ingsporadiclate-onsetAD[1,5,6],anddysregulation ofinsulinsignalingisthoughttocontributetoa cascade of neuropathological changes that promote amyloidogenic processing, neurotoxicity, and brain…”
InfluentialType 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“APOE (cid:2) 4 carriage is associated with hypometabolism [38–40], higher amyloid burden [41] and gray matter atrophy in AD-sensitive regions [42], and as shown by animal studies, may be particularly deleterious to the hippocampus and hippocampal-dependent tasks such as the Morris water maze,…”
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954 · cited 1×
“thermore, over the past decade, several studies have shown that A soluble oligomers have neurotoxic effects that include disruption of synaptic integrity and synaptic plasticity [30, 31], as well as alteration of molecular and cellular pathways integral to memory formation [32–34].”
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600549103 · Cited by 912
Insulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790 · cited 1×
“APOE 4 carriage is associated with hypometabolism [38–40], higher amyloid burden [41] and gray matter atrophy in AD-sensitive regions [42], and as shown by animal studies, may be particularly deleterious to the hippocampus and hippocampal-dependent tasks such as the Morris water maze, object recognition, and context f…”
Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639 · cited 2×
“Cognitively healthy individuals with reduced peripheral insulin function show subtle cognitive deficits, reduced cerebral glucose metabolism, and diminished cerebrocortical activity [15, 16].”
Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama Study
Matsuzaki, T., Sasaki, K., Tanizaki, Y., Hata, J., Fujimi, K., Matsui, Y., Sekita, A., Suzuki, S. O., Kanba, S., Kiyohara, Y., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181eee25f · Cited by 432
Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368
Self-citationChen, Y., Durakoglugil, M. S., Xian, X., & Herz, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914984107 · Cited by 368
Convit, A., de Asis, J., de Leon, M. J., Tarshish, C. Y., De Santi, S., & Rusinek, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00107-4 · Cited by 359 · cited 1×
“Long-term memory tasks, such as the one examined here, are dependent on the hippocampus, a medial temporal lobe structure negatively affected by IR [71–73] and among the first regions to show structural and functional changes in AD [74–77].”
Convit, A., Wolf, O. T., Tarshish, C., & de Leon, M. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336073100 · Cited by 347
Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study
Schrijvers, E. M. C., Witteman, J. C. M., Sijbrands, E. J. G., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4f6 · Cited by 328
Impaired insulin action in the human brain: causes and metabolic consequences
Heni, M., Kullmann, S., Preissl, H., Fritsche, A., & Häring, H.-U. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.173 · Cited by 245
Tschritter, O., Preissl, H., Hennige, A. M., Stumvoll, M., Porubska, K., Frost, R., Marx, H., Klösel, B., Lutzenberger, W., Birbaumer, N., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604404103 · Cited by 223 · cited 1×
“Cognitively healthy individuals with reduced peripheral insulin function show subtle cognitive deficits, reduced cerebral glucose metabolism, and diminished cerebrocortical activity [15,16].”
Thambisetty, M., Metter, E. J., Yang, A., Dolan, H., Marano, C., Zonderman, A. B., Troncoso, J. C., Zhou, Y., Wong, D. F., Ferrucci, L., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.284 · Cited by 155 · cited 2×
“Some studies have failed to find a relationship between IR and amyloid pathology [21, 25]; however, the participants studied here are younger than in other studied cohorts, consistent with a possible early relationship between IR and A 42 generation.”
Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ
Zhao, W.-Q., Lacor, P. N., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011015 · Cited by 154
Mosconi, L., Rinne, J. O., Tsui, W. H., Berti, V., Li, Y., Wang, H., Murray, J., Scheinin, N., Någren, K., Williams, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914141107 · Cited by 135
Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease
Honea, R. A., Swerdlow, R. H., Vidoni, E. D., Goodwin, J., & Burns, J. M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918cb · Cited by 106 · cited 1×
“Likewise, parental family history of dementia due to AD is associated with pathological changes in AD-sensitive brain regions, even among individuals who are cognitively asymptomatic [46–52].”
Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease
Honea, R. A., Swerdlow, R. H., Vidoni, E. D., & Burns, J. M. (2011) · Neurology · doi:10.1212/wnl.0b013e31820e7b74 · Cited by 99 · cited 1×
“Likewise, parental family history of dementia due to AD is associated with pathological changes in AD-sensitive brain regions, even among individuals who are cognitively asymptomatic [46–52].”
Adluru, N., Destiche, D. J., Lu, S. Y.-F., Doran, S. T., Birdsill, A. C., Melah, K. E., Okonkwo, O. C., Alexander, A. L., Dowling, N. M., Johnson, S. C., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.04.008 · Cited by 85
Self-citationHippocampus-related cognitive impairments in young apoE4 targeted replacement mice
Salomon-Zimri, S., Boehm-Cagan, A., Liraz, O., & Michaelson, D. M. (2013) · Neurodegenerative Diseases · doi:10.1159/000354777 · Cited by 34 · cited 1×
“…[38–40], higher amyloid burden [41] and gray matter atrophy in AD-sensitive regions [42], and as shown by animal studies, may be particularly deleterious to the hippocampus and hippocampal-dependent tasks such as the Morris water maze, object recognition, and context fear conditioning [43].”
Cited by
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
Cognitive dysfunction: a growing link between diabetes and Alzheimer’s disease
Jash, K., Gondaliya, P., Kirave, P., Kulkarni, B., Sunkaria, A., & Kalia, K. (2020) · Drug Development Research · doi:10.1002/ddr.21579 · Cited by 119
Gleason, C. E., Zuelsdorff, M., Gooding, D. C., Kind, A. J. H., Johnson, A. L., James, T. T., Lambrou, N. H., Wyman, M. F., Ketchum, F. B., Gee, A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12511 · Cited by 104
Self-citation
Metadata
- Authors
- Hoscheidt, S. M., Starks, E. J., Oh, J. M., Zetterberg, H., Blennow, K., Krause, R. A., Gleason, C. E., Puglielli, L., Atwood, C. S., Carlsson, C. M., Asthana, S., Johnson, S. C., & Bendlin, B. B.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-04-12
- Volume
- 52
- Issue
- 4
- Pages
- 1373-1383
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2338520572
- Cited by
- 81
- References
- 30
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.